Pharmacological treatment reduces refracture rates in older adults with hip fractures, especially when initiated through FLS. Although bisphosphonates are most commonly studied, anabolic and other antiresorptive agents also show benefits. Improved reporting on BMD follow-up and adherence is needed to guide long-term osteoporosis management.
Hosseinzadeh et al. (Sun,) studied this question.